

## **Supplementary data**

**Toxic effect and inability of L-homoserine to be a nitrogen source for growth of *Escherichia coli* resolved by a combination of *in vivo* evolution engineering and omics analysis.**

Ceren Alkim<sup>1,2</sup>, Daniele Farias<sup>1</sup>, Julie Fredonnet<sup>2</sup>, Helene Serrano-Bataille<sup>2</sup>, Pauline Herviou<sup>2</sup>, Marc Picot<sup>1</sup>, Nawel Slama<sup>2</sup>, Sebastien Dejean<sup>3</sup>, Nicolas Morin<sup>2</sup>, Brice Enjalbert<sup>1</sup> and Jean M François<sup>1,2\*</sup>

<sup>1</sup>Toulouse Biotechnology Institute (TBI), Université de Toulouse, CNRS, INRA, INSA, Toulouse, France, 135 Avenue de Rangueil, F-31077 Toulouse, France;

<sup>2</sup>Toulouse White Biotechnology center (TWB), UMS-INSA-INRA-CNRS, 135 avenue de Rangueil, F-31077 Toulouse

<sup>3</sup>Institut de Mathématique Toulouse, 135 avenue de Rangueil, 31077 Toulouse, cedex 04

### **Key words:**

*Escherichia coli*, Microbial physiology, L-homoserine, genetic regulation, transcriptomics, evolutionary engineering

Email address: [alkim@insa-toulouse.fr](mailto:alkim@insa-toulouse.fr)  
[julie.fredonnet@inrae.fr](mailto:julie.fredonnet@inrae.fr)  
[helene.serrano@micro-pep.com](mailto:helene.serrano@micro-pep.com)  
[daniele.farias@insa-toulouse.fr](mailto:daniele.farias@insa-toulouse.fr)  
[pauline.herviou@inrae.fr](mailto:pauline.herviou@inrae.fr)  
[marc.picot@inrae.fr](mailto:marc.picot@inrae.fr)  
[nawel.slama@inrae.fr](mailto:nawel.slama@inrae.fr)  
[sebastien.dejean@math.univ-toulouse.fr](mailto:sebastien.dejean@math.univ-toulouse.fr)  
[nicolas.morin@inrae.fr](mailto:nicolas.morin@inrae.fr)  
[brice.enjalbert@insa-toulouse.fr](mailto:brice.enjalbert@insa-toulouse.fr)  
[fran\\_jm@insa-toulouse.fr](mailto:fran_jm@insa-toulouse.fr) or [jean.marie-francois@inrae.fr](mailto:jean.marie-francois@inrae.fr)

\*Address for correspondence: [fran\\_jm@insa-toulouse.fr](mailto:fran_jm@insa-toulouse.fr)

**Table S1:** List of *E. coli* Strain and plasmids used in this study

Strain	Genotype	Source
MG1655	K12 F <sup>-</sup> λ <sup>-</sup> <i>ilvG</i> <sup>-</sup> <i>rfb-50</i> <i>rph-1</i> fhuA2 [lon] <i>ompT</i> <i>gal</i> (λ DE3) [dcm] ΔhsdS λ DE3 = λ	ATCC 47076
BL21(DE3)	sBamH <sub>I</sub> λEcoRI-B int::(lacI::PlacUV5::T7 gene1) i21 Δnir5 F-, endA1, supE44, thi-1, recA1, relA1, gyrA96, phoA,	New England Biolabs
Stellar	Φ80d lacZΔ M15, Δ (lacZYA - argF) U169, Δ (mrr - hsdRMS - mcrBC), ΔmcrA, λ-	New England Biolabs
NEB 5-alpha	fhuA2 Δ(argF-lacZ)U169 phoA glnV44 Φ80Δ (lacZ)M15 gyrA96 recA1 relA1 endA1 thi-1 hsdR17 Δ(arad-leu) 7697 arad139 fhuA ΔlacX74 galK16 galE15	New England Biolabs
DH10B	e14- φ80dlacZΔM15 recA1 relA1 endA1 nupG rpsL (StrR) rph spoT1 Δ (mrr-hsdRMS-mcrBC) can::CBD fhuA2 [lon] <i>ompT</i> <i>gal</i> (λ DE3) [dcm] arnA::CBD	New England Biolabs
NiCo21(DE3)	slyD::CBD glmS6Ala ΔhsdS λ DE3 = λ sBamH <sub>I</sub> λEcoRI-B int::(lacI::PlacUV5::T7 gene1) i21 Δnir5 Δ(arad-araB) 567 Δ(rhaD-rhaB) 568 ΔlacZ4787 (::rrnB-3) hsdR514 rph-1	New England Biolabs
JS200	SC-18 recA718 polA12 uvrA155 trpE65 lon-11 sulA1	{Camps, 2003 #10838}
MG1655 ΔthrL	MG1655 deleted of <i>thrL</i> by phage transduction	This work
4E	Evolved MG1655 on L-homoserine	This work
4E ΔthrB	4E deleted of <i>thrB</i> by phage transduction	This work
4E Δtdh	4E deleted of <i>tdhL</i> by phage transduction	This work
4E Δkbl	4E deleted of <i>kbl</i> by phage transduction	This work
4E ΔgcvP	4E deleted of <i>gcvP</i> by phage transduction	This work
4E Δgdha ΔgltB	4E deleted of <i>gdha</i> <i>gltB</i> by phage transduction	This work
4E Δnac	4E deleted of <i>nac</i> by phage transduction	This work
MG1655 <i>thrL</i> *	MG1655 with replacement of wild type <i>thrL</i> by the truncated version <i>thrL</i> * by CRISPR-cas9	This work
BW25113 ΔlivJ	F-, Δ(arad-araB)567, ΔlacZ4787(::rrnB-3), λ-, ΔlivJ790::kan, rph-1, Δ(rhaD-rhaB)568, hsdR514	{Baba, 2006 #9562}
BW25113 ΔlivK	F-, Δ(arad-araB)567, ΔlacZ4787(::rrnB-3), λ-, ΔlivK788::kan, rph-1, Δ(rhaD-rhaB)568, hsdR514	{Baba, 2006 #9562}
BW25113 ΔtdccC	F-, Δ(arad-araB)567, ΔlacZ4787(::rrnB-3), λ-, ΔtdccC732::kan, rph-1, Δ(rhaD-rhaB)568, hsdR514	{Baba, 2006 #9562}

**Table S2:** listing of plasmid used and constructed in this work

Plasmids	description	Source/reference
pET-28a(+)	Expression of different genes	Novagen
pET-28a alaC	pET-28-a(+) derivative carrying <i>E. coli</i> <i>alaC</i> gene	This study
pET-28a alaC <sup>R78G</sup>	pET-28-a(+) derivative carrying <i>E. coli</i> <i>alaC<sup>R78G</sup></i> gene	This study
pCP20	plasmid used for removing Kan cassette	{Cherepanov, 1995 #9564}
pCas	Plasmid used for Cas9 and lambda RED, constitutive and inducible expression, respectively	{Jiang, 2015 #10453}
pTargetF	Plasmid that express sgRNA constitutively	{Jiang, 2015 #10453}
pTargetF- <i>thrL</i> *	Plasmid used for targeting the region to be replaced by CRISPR-Cas9 method	This study

**Table S3:** listing of primers used in this work


oligonucleotide	description	Gene target
thrL-vrf-fw	Verification of <i>thrL</i> deletion	AACGGGCAATATGTCTCTGTG
thrL-vrf-rev		GATGTACCGCCGAACCTCAACA
thrL-seq-fw	To sequence <i>thrL-thrL*</i> up and downstream regions	AGCTTTTCATTCTGACTGC
thrL-seq-rev		CAGAAAACGTTCTGCATT
thrL*-BamHI-fw	To clone <i>thrL*</i> into pET-28a(+)	ATTGTTGGATCCATGAAACGCATTAGCACC
thrL*-HindIII-rev		GTTCAAAGCTTTACCTCGTTACCTTGG
thrL-donneur-fw	To amplify <i>thrL*</i> donneur DNA	AGCTTTTCATTCTGACTGCAA
thrL-donneur-rev		CAAATTCCCTGATCGACGAAAG
oligo-pTarget-thrL*	To construct pTargetF- <i>thrL*</i>	GTCCTAGGTATAACTAGT <b>CGCACCGTTACCTGTGG</b> <b>TAA</b> TTTAGAGCTAGAAATAGC*
pTargetF-rev		ACTAGTATTATACTAGGACTGAG
gRNArvbis	To sequence pTargetF- <i>thrL*</i>	GTCGTTGATCAAAGCTGCCGCGTTG
nac-vrf-fw	Verification of <i>nac</i> deletion	GGCAGTGCATGGTGATGTCAAAG
nac-vrf-rev		GTAATGCTTGCCCCGGTTCACT
tbl-vrf-fw	Verification of <i>tbl</i> deletion	CAATCATCATTATGCCAGCCA
tbl-vrf-rev		GCGGCAATGACCACAGGTGA
locus_tdh_FOR	Verification of <i>tdh</i> deletion	TATGCCAACACGATATGCAGGAGC
locus_tdh_REV		TCATGCCCGCATTATATAACGG
Ec_gltB_Fwd	Verification of <i>gltB</i> deletion	AACAAGGGGGCGAATGCGAG
Ec_gltB_Rev		TTGCTACCCCTTACTGCGCCTG
Ec_gdhA_Fwd	Verification of <i>gdhA</i> deletion	GCAAAAGCACATGACATAAACAA
Ec_gdhA_Rev		GCCATCAGGCATTACAACCTTA

\*N20 region is indicated by red color


**Table S4:** Kinetic properties of AlaC and AlaC<sup>R78G</sup> variant\*

Enzyme	Substrate	K <sub>M</sub> (mM)	V <sup>max</sup> (μmol/min/mg protein)	k <sub>cat</sub> (s <sup>-1</sup> )	k <sub>cat</sub> /K <sub>M</sub> (s <sup>-1</sup> . M <sup>-1</sup> )
AlaC	alanine	5.2	0.80	0.65	125
	α-ketoglutarate	0.09	0.65	0.53	5880
	pyruvate	0.10	0.64	0.52	5200
	glutamate	7.2	0.62	0.55	76
AlaC <sup>R78G</sup>	alanine	2.8	1.1	0.92	328
	α-ketoglutarate	0.08	1.15	0.94	17638
	pyruvate	0.13	1.15	0.94	7230
	glutamate	2.20	1.20	1.06	482



\*Data are the mean of two independent experiments





**Figure S1:** Homoserine causes growth inhibition when added to a mineral medium containing another source of nitrogen (ammonium ions). The growth was carried out in M9 medium buffered at pH 7.0 with 100 mM MOPS containing 0.4% (w/v) glucose at 30°C in a Bioteck microplate reader.




**Figure S2.** Deletion of *livJ* or *livK* encoding branched -chain amino acids transporters, or *tdcC* encoding the threonine importer does not abolish the growth inhibitory effect of homoserine. The growth was made in M9 buffered at pH 7.0 with 100 mM MOPS containing 2% (w/v) glucose




**Figure S3:** Homoserine-resistant WT MG1655 was obtained by evolutionary engineering. In (A), the culture was firstly adapted in a turbidostat mode to grow in M9 medium buffered at pH 7.0 with sodium phosphate/ citrate containing 0.2% (w/v glucose) and L-aspartate (10mM) as nitrogen source, until reaching the highest and stable growth rate. In (B), a medium swap mode was applied corresponding to pulse addition of a restrictive M9 medium with L-homoserine as the nitrogen source (10 mM) at constant a growth rate. Adaptation of the population on homoserine was obtained when % of pulse of restrictive medium reached 100%. In (C), the population was further adapted to L-homoserine restrictive medium using a turbidostat mode until it yielded a stable specific growth rate.

**A****B**

**Figure S4:** (A) *thrLABC* operon. Genes, terminator sites, transcription start site and transcription regulators of this operon were demonstrated. (Keseler et al. (2017), "EcoCyc: reflecting new knowledge about Escherichia coli K-12", Nucleic Acids Research 45:D543-50.). (B) sequencing data at the *thrL* locus of the wild type MG1655 and the HMSRCE4 strain. The blue bar shows the wild type *thrL* gene, while the red bar show the *thrL\** allele in HMSRCE4, with the deleted region highlighted by the yellow bar.





**Figure S6 :** Sensitivity of  $\text{thrL}^*$  strain to homoserine is restored upon deletion of  $\text{thrB}$  encoding homoserine linase. Growth was carried out in M9 medium at 37°C in the presence of different concentration of L-homoserine as indicated in the figure.

